Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET [Phase 3]

View source ↗

Summary

Phase 3 study to evaluate Lutathera (lutetium Lu-177 dotatate) in patients with grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors. Results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-10